Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for BiomX Inc. (PHGE : AMEX)

• Company Description    BiomX Ltd is a clinical stage microbiome company. It engages in developing both natural and engineered phage cocktails designed to target and destroy bacteria which affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as IBD, PSC and cancer. BiomX Ltd, formerly known as Chardan Healthcare Acquisition Corp., is based in Ness Ziona, Israel. Number of Employees: 57

• Price / Volume Information    Yesterday's Closing Price: $1.87 Daily Weekly Monthly 20 Day Moving Average: 122,879 shares Shares Outstanding: 1.53 (millions) Market Capitalization: $2.85 (millions) Beta: 1.60 52 Week High: $22.06 52 Week Low: $1.50 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -60.80% -60.73% 12 Week -84.13% -84.38% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 22 EINSTEIN ST. FLOOR 4 - NESS ZIONA,L3 7414003 ISR ph: 972-72-394-2377 fax: - assafo@biomx.com http://www.biomx.com

• General Corporate Information    Officers Jonathan Solomon - Chief Executive Officer and Director Russell Greig - Chairman Marina Wolfson - Chief Financial Officer Susan Blum - Director Jesse Goodman - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED PRODUCTS Sector: Medical CUSIP: 09090D509 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/24/26 Share - Related Items Shares Outstanding: 1.53 Most Recent Split Date: 11.00 (0.05:1) Beta: 1.60 Market Capitalization: $2.85 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-4.61 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-5.85 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/24/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 70.10% vs. Previous Quarter: -252.63% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 12/31/25 - - 09/30/25 - -2,923.50 06/30/25 - -621.75 ROA 12/31/25 - - 09/30/25 - -71.43 06/30/25 - -103.53 Current Ratio 12/31/25 - - 09/30/25 - 1.70 06/30/25 - 2.66 Quick Ratio 12/31/25 - - 09/30/25 - 1.70 06/30/25 - 2.66 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Book Value 12/31/25 - - 09/30/25 - -5.77 06/30/25 - 0.37 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - - 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©